Publications

Detailed Information

한국형 DUR의 효과적 추진전략 : Strategy for establishing an effective Korean drug utilization review system

DC Field Value Language
dc.contributor.author최남경-
dc.contributor.author박병주-
dc.date.accessioned2012-06-25T02:44:40Z-
dc.date.available2012-06-25T02:44:40Z-
dc.date.issued2010-12-
dc.identifier.citationJOURNAL OF THE KOREAN MEDICAL ASSOCIATION; Vol.53 12; 1130-1138ko_KR
dc.identifier.issn1975-8456-
dc.identifier.urihttps://hdl.handle.net/10371/77371-
dc.description.abstractDrug utilization review (DUR) system has been defined as "structured, ongoing initiatives that interpret patterns of drug use in relation to predetermined criteria, and attempt to prevent or minimize inappropriate prescribing." This paper introduces the concept, purpose, and effective application of OUR in Korea. OUR can be classified as retrospective OUR, prospective OUR, and concurrent OUR based on the time direction of applying OUR. OUR can also be classified as quantitative DUR defined by retrospective OUR using databases including previously prescribed medicines, and qualitative DUR defined by OUR reflecting patient`s clinical condition. We described the history of developing OUR in the United States and the Europe. Finally current status of DUR in Korea is described and the strategy of future settlement of DUR system in Korea is suggested.ko_KR
dc.language.isokoko_KR
dc.publisherKOREAN MEDICAL ASSOCko_KR
dc.subjectDrug utilization review systemko_KR
dc.subjectKoreako_KR
dc.subjectDrug safetyko_KR
dc.title한국형 DUR의 효과적 추진전략ko_KR
dc.title.alternativeStrategy for establishing an effective Korean drug utilization review systemko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthorChoi, Nam-Kyong-
dc.contributor.AlternativeAuthorPark, Byung-Joo-
dc.identifier.doi10.5124/jkma.2010.53.12.1130-
dc.citation.journaltitleJOURNAL OF THE KOREAN MEDICAL ASSOCIATION-
dc.description.citedreferenceKIM DS, 2010, HIRA POLICY TREND, V4, P14-
dc.description.citedreferencePARK JY, 2010, HIRA POLICY TREND, V4, P23-
dc.description.citedreference*INT SOC PHARM, 2010, EUR DRUG UT RES GROU-
dc.description.citedreferenceCHOI BC, 2009, HIRA POLICY TREND, V3, P11-
dc.description.citedreferenceSHIN KS, 2009, HIRA POLICY TREND, V3, P22-
dc.description.citedreferencePARK BJ, 2008, J PHARMACOEPIDEMIOL, V1, P13-
dc.description.citedreferenceYeom JH, 2005, ANN PHARMACOTHER, V39, P1918, DOI 10.1345/aph.1E674-
dc.description.citedreferenceHENNESSY S, 2005, PHARMACOEPIDEM DR S, P833-
dc.description.citedreferencePARK BJ, 1999, KOREAN J CLIN PHARM, V7, P3-
dc.description.citedreferenceERWIN WG, 1991, CLIN PHARMACOL THER, V50, P596-
dc.description.tc0-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share